EP0973911A1 - MUTANT $i(msbB) or $i(htrB) GENES - Google Patents
MUTANT $i(msbB) or $i(htrB) GENESInfo
- Publication number
- EP0973911A1 EP0973911A1 EP98902105A EP98902105A EP0973911A1 EP 0973911 A1 EP0973911 A1 EP 0973911A1 EP 98902105 A EP98902105 A EP 98902105A EP 98902105 A EP98902105 A EP 98902105A EP 0973911 A1 EP0973911 A1 EP 0973911A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- salmonella
- gene
- micro
- organism
- msbb
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 101100021843 Shigella flexneri lpxM1 gene Proteins 0.000 title claims abstract description 99
- 101100021844 Shigella flexneri lpxM2 gene Proteins 0.000 title claims abstract description 99
- 101150060640 lpxM gene Proteins 0.000 title claims abstract description 99
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 68
- 101100451792 Bacillus subtilis (strain 168) htrB gene Proteins 0.000 title claims abstract description 16
- 101150011311 lpxL gene Proteins 0.000 title claims abstract description 16
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims abstract description 64
- 241000607142 Salmonella Species 0.000 claims abstract description 50
- 101150062294 htrB gene Proteins 0.000 claims abstract description 41
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 39
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 34
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 34
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 34
- 230000002829 reductive effect Effects 0.000 claims abstract description 34
- 231100000419 toxicity Toxicity 0.000 claims abstract description 30
- 230000001988 toxicity Effects 0.000 claims abstract description 30
- 244000005700 microbiome Species 0.000 claims description 74
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 claims description 38
- 229960005486 vaccine Drugs 0.000 claims description 26
- 241000588724 Escherichia coli Species 0.000 claims description 20
- 102000004127 Cytokines Human genes 0.000 claims description 18
- 108090000695 Cytokines Proteins 0.000 claims description 18
- 125000002252 acyl group Chemical group 0.000 claims description 11
- 241000607768 Shigella Species 0.000 claims description 10
- 230000002238 attenuated effect Effects 0.000 claims description 10
- 241000589291 Acinetobacter Species 0.000 claims description 9
- 241000606750 Actinobacillus Species 0.000 claims description 9
- 241000607534 Aeromonas Species 0.000 claims description 9
- 241000588807 Bordetella Species 0.000 claims description 9
- 241000589562 Brucella Species 0.000 claims description 9
- 108020004414 DNA Proteins 0.000 claims description 9
- 241000588914 Enterobacter Species 0.000 claims description 9
- 241000589565 Flavobacterium Species 0.000 claims description 9
- 241000606790 Haemophilus Species 0.000 claims description 9
- 241000588748 Klebsiella Species 0.000 claims description 9
- 241000588621 Moraxella Species 0.000 claims description 9
- 241000588653 Neisseria Species 0.000 claims description 9
- 241000606860 Pasteurella Species 0.000 claims description 9
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 9
- 241000589516 Pseudomonas Species 0.000 claims description 9
- 241000607720 Serratia Species 0.000 claims description 9
- 241000607598 Vibrio Species 0.000 claims description 9
- 241000607734 Yersinia <bacteria> Species 0.000 claims description 9
- 241001138501 Salmonella enterica Species 0.000 claims description 8
- 241000607356 Salmonella enterica subsp. arizonae Species 0.000 claims description 8
- 241000607662 Salmonella enterica subsp. enterica serovar Abortusequi Species 0.000 claims description 8
- 241000522522 Salmonella enterica subsp. enterica serovar Abortusovis Species 0.000 claims description 8
- 241000596091 Salmonella enterica subsp. enterica serovar Anatum Species 0.000 claims description 8
- 241000592151 Salmonella enterica subsp. enterica serovar Bovismorbificans Species 0.000 claims description 8
- 241000392514 Salmonella enterica subsp. enterica serovar Dublin Species 0.000 claims description 8
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 claims description 8
- 241000607132 Salmonella enterica subsp. enterica serovar Gallinarum Species 0.000 claims description 8
- 241001355131 Salmonella enterica subsp. enterica serovar Hadar Species 0.000 claims description 8
- 241000786444 Salmonella enterica subsp. enterica serovar Havana Species 0.000 claims description 8
- 241000210647 Salmonella enterica subsp. enterica serovar Montevideo Species 0.000 claims description 8
- 241001546666 Salmonella enterica subsp. enterica serovar Newport Species 0.000 claims description 8
- 241000531795 Salmonella enterica subsp. enterica serovar Paratyphi A Species 0.000 claims description 8
- 241000577475 Salmonella enterica subsp. enterica serovar Paratyphi C Species 0.000 claims description 8
- 241000607683 Salmonella enterica subsp. enterica serovar Pullorum Species 0.000 claims description 8
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 claims description 8
- 241000204910 Salmonella enterica subsp. salamae serovar Sofia Species 0.000 claims description 7
- 229930027917 kanamycin Natural products 0.000 claims description 7
- 229960000318 kanamycin Drugs 0.000 claims description 7
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 7
- 229930182823 kanamycin A Natural products 0.000 claims description 7
- 231100000518 lethal Toxicity 0.000 claims description 7
- 230000001665 lethal effect Effects 0.000 claims description 7
- 231100000252 nontoxic Toxicity 0.000 claims description 7
- 230000003000 nontoxic effect Effects 0.000 claims description 7
- 108020004511 Recombinant DNA Proteins 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 4
- 230000021615 conjugation Effects 0.000 claims description 3
- 238000010353 genetic engineering Methods 0.000 claims description 3
- 238000010361 transduction Methods 0.000 claims description 3
- 230000026683 transduction Effects 0.000 claims description 3
- 238000010367 cloning Methods 0.000 claims description 2
- 239000013599 cloning vector Substances 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 241001467018 Typhis Species 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 239000002158 endotoxin Substances 0.000 description 28
- 241000894006 Bacteria Species 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 25
- 208000015181 infectious disease Diseases 0.000 description 20
- 229920006008 lipopolysaccharide Polymers 0.000 description 19
- 241001167018 Aroa Species 0.000 description 16
- 101100491986 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) aromA gene Proteins 0.000 description 16
- 101150037081 aroA gene Proteins 0.000 description 16
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 13
- 102100040247 Tumor necrosis factor Human genes 0.000 description 12
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 11
- 230000004044 response Effects 0.000 description 11
- 230000035772 mutation Effects 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 238000011725 BALB/c mouse Methods 0.000 description 7
- 208000037386 Typhoid Diseases 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 201000008297 typhoid fever Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000010933 acylation Effects 0.000 description 6
- 238000005917 acylation reaction Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- JYZJYKOZGGEXSX-UHFFFAOYSA-N 2-hydroxymyristic acid Chemical class CCCCCCCCCCCCC(O)C(O)=O JYZJYKOZGGEXSX-UHFFFAOYSA-N 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 150000004665 fatty acids Chemical class 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000013459 approach Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229960003753 nitric oxide Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 241000271566 Aves Species 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 206010039438 Salmonella Infections Diseases 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 231100000225 lethality Toxicity 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 206010039447 salmonellosis Diseases 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 108091006619 SLC11A1 Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000007689 endotoxicity Effects 0.000 description 2
- 150000002190 fatty acyls Chemical group 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000003226 mitogen Substances 0.000 description 2
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- VOBNSQKMDIOJTQ-UHFFFAOYSA-N 2-aminoethyl phosphono hydrogen phosphate Chemical compound NCCOP(O)(=O)OP(O)(O)=O VOBNSQKMDIOJTQ-UHFFFAOYSA-N 0.000 description 1
- UZGRZSHGRZYCQV-UHFFFAOYSA-N 4,6-dichloro-1,3-benzothiazol-2-amine Chemical compound C1=C(Cl)C=C2SC(N)=NC2=C1Cl UZGRZSHGRZYCQV-UHFFFAOYSA-N 0.000 description 1
- 102100039140 Acyloxyacyl hydrolase Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010061765 Chromosomal mutation Diseases 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- ATRNZOYKSNPPBF-UHFFFAOYSA-N D-beta-hydroxymyristic acid Natural products CCCCCCCCCCCC(O)CC(O)=O ATRNZOYKSNPPBF-UHFFFAOYSA-N 0.000 description 1
- 230000008836 DNA modification Effects 0.000 description 1
- 230000007023 DNA restriction-modification system Effects 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 238000006595 Griess deamination reaction Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 101150038013 PIR gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 1
- 241000191043 Rhodobacter sphaeroides Species 0.000 description 1
- 241000701835 Salmonella virus P22 Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010008855 acyloxyacyl hydrolase Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940031567 attenuated vaccine Drugs 0.000 description 1
- 229960001212 bacterial vaccine Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- 230000008711 chromosomal rearrangement Effects 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 125000000600 disaccharide group Chemical group 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000008816 organ damage Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 101150025220 sacB gene Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/255—Salmonella (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/42—Salmonella
Definitions
- Mutant msbB or htrB genes The present invention relates to nucleic acid for a mutant msbB gene or a mutant htrB gene, a recombinant DNA construct comprising the nucleic acid, a micro-organism comprising a mutant msbB or htrB gene, an inactivated msbB or htrB gene or lacking a msbB or htrB gene, and uses thereof, particularly, but not exclusively, its use in a vaccine.
- LPS Lipopolysaccharide
- lipid A molecules may be divided into hydrophilic and hydrophobic domains.
- the hydrophilic region consists of a 1-6 linked D-glucosamine (GlcN) disaccharide backbone substituted by phosphate groups at positions 1 and 4' , which may in turn be linked to, or replaced by, pyrophosphorylethanolamine or 4-amino-4- deoxy-L-arabinose.
- the hydrophobic region consists of fatty acids and these may vary between species.
- the lipid A has a fatty acylation pattern in which the 2 and 2' amino groups and the 3 and 3' hydroxyl groups on the diglucosamine are each linked to 3-hydroxytetradecanoic acid (3-OH- 14:0).
- the 2'- linked fatty acid is further substituted at the 3-hydroxyl group by dodecanoic acid (12:0) and the 3' fatty acid is again further substituted at the 3-hydroxyl group by tetradecanoic acid (14:0) (1,2).
- dodecanoic acid (12:0) and the 3' fatty acid is again further substituted at the 3-hydroxyl group by tetradecanoic acid (14:0) (1,2).
- lipid A is non-toxic and differs from toxic lipid A only in the pattern of fatty acyl substitutions (1,2).
- treatment of lipid A with hydroxide ion cleaves the secondary acyl chains from the molecule with consequent detoxification.
- an acyloxyacyl hydrolase is present in neutrophils that catalyses precisely this cleavage and is probably one of the mechanisms responsible for detoxifying lipid A in vivo.
- both these systems are naturally occurring and there is no indication of how these observations could be applied to other systems.
- EP-A-0 650 733 describes an attenuated vaccine for avian species comprising a micro-organism which may be Salmonella or E. coli amongst others.
- the approach taken is to use a micro-organism which exhibits auxotrophy to one or more growth factors, such that it is incapable of growing on a minimal medium in the absence of said one or more growth factors.
- nucleic acid for a mutant msbB gene derivable from Salmonella which results in loss of MsbB protein or loss of function of the protein, which in turn results in a lipid A molecule having reduced toxicity compared to the wild-type lipid A molecule.
- nucleic acid for a mutant htrB gene derivable from Salmonella which results in loss of HtrB protein or loss of function of the protein, which in turn results in a lipid A molecule having reduced toxicity compared to the wild-type lipid A molecule.
- the mutant msbB or htrB gene results in loss of MsbB or HtrB protein respectively, which in turn results in the biosysnthesis of a lipid A molecule with a reduced ability to induce cytokines.
- the lipid A molecule is one which forms part of LPS. Whilst not wishing to be bound by any theory it is believed that the loss of the msbB encoded protein or the loss of function of the msbB encoded protein will give rise to a lipid A molecule lacking at least secondary acylation of the hydroxyl group of the 2 '-linked hydroxytetradecanoic acid of the lipid A. Similarly, it is believed that the loss of the htrB encoded protein or loss of function of the HtrB protein will give rise to a lipid A molecule lacking at least secondary acylation of the hydroxyl group of the 3'-linked hydroxytetradecanoic acid of the lipid A molecule.
- the lipid A is deficient in at least one of the secondary acyl chains which are usually associated with a lipid A domain of a lipopolysaccharide.
- the lipid A molecule lacks both secondary acyl chains.
- the mutant is derivable, or derived, from Salmonella, Shigella, Klebsiella, Enterobacter, Serratia, Proteus, Yersinia, Vibrio, Aeromonas, Pasteurella, Pseudomonas, Acinetobacter, Moraxella, Flavobacterium, Bordetella, Actinobacillus, Neisseria, Brucella, Haemophilus or Escherichia coli.
- the mutant may be derivable, or in a particularly preferred embodiment is derived, from Salmonella.
- the mutant can be arrived at by mutating a wild type Salmonella micro-organism or more specifically its msbB or htrB gene.
- synthetic nucleic acid fall within the scope of the present invention.
- the mutant may be sequenced and the nucleic acid of interest reproduced, e.g. synthetically, using techniques well known to the skilled worker. This is also true when the mutant is derived from a micro-organism other than Salmonella.
- One preferred method uses genetic manipulation of msbB or htrB by insertion of a kanamycin resistance cassette to inactivate the gene, conjugation of the inactivated gene into the recipient to be mutated on a suicide vector, followed by P22 transduction into other recipients.
- the microorganism is Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi A or C, Salmonella schottmulleri, Salmonella choleraesuis, Salmonella montevideo, Salmonella newport, Salmonella enteritidis, Salmonella gallinarum, Salmonella pullorum, Salmonella abortusovi, Salmonella abortus-equi, Salmonella dublin, Salmonella sofia, Salmonella havana, Salmonella bovis-morbificans , Salmonella hadar. Salmonella arizonae or Salmonella anatum.
- the microorganism is S. typhimurium, and preferably the strain is C5, SL1344 or HWSH.
- the mutation or loss of protein is not lethal for growth of a microorganism.
- This has the advantage that the micro-organism can be easily cultured without having to add supplements to the medium.
- viable bacterial are produced after alteration of a component of the lipid A molecule.
- the lipid A molecule has a reduced ability to induce a cytokine response.
- Ability to induce a cytokine response is a conventional toxicity measure.
- the lipid A molecules produced by the present invention have the ability to reduce cytokine induction down to about l A- l A of that induced by wild-type lipid A molecules.
- the lipid A molecule and/or micro-organism induces less TNF- ⁇ and/or less IL-ljS and/or less NO. More preferably the lipid A molecule induces at least 5-fold less TNF- ⁇ and at least half as much IL-l ⁇ as the corresponding wild-type. In another preferred embodiment the lipid A molecule induces at least half as much NO as the corresponding wild-type.
- the present invention provides for the toxicity to be substantially reduced. In an especially preferred embodiment there is substantially no toxicity.
- the micro-organism of the present invention kills a BALB/c mouse when the population of the micro-organism in the liver and/or spleen reaches about 10 9 per organ. In fact it actually only kills a proportion of the infected mice, around 5-10%, even at such a high level of 10 9 per organ. This can be compared to the wild-type where a micro-organism population of about 10 8 per organ is sufficient to kill all mice infected. It is preferable to compare the reduced toxicity of the lipid A molecule arrived at using the present invention and/or toxicity of the micro-organism of the present invention against the toxicity of a lipid A molecule produced by the parent wild-type.
- parent wild-type we mean the micro-organism from which the mutant was derived, e.g. the wild-type micro-organism which was used to produce the mutant, or the wild-type micro-organism in which the mutant was engineered.
- nucleic acid derived from Salmonella and encoding for a mutant msbB gene or a mutant htrB gene which results in a lipid A molecule having reduced toxicity compared to the lipid A molecule produced by the respective msbB encoded protein or htrB encoded protein encoded for by the corresponding Salmonella msbB/htrB gene from which the mutant is derived.
- the mutant msbB and htrB genes of the present invention may result in a polypeptide which is truncated with respect to the polypeptide encoded by the non-mutated gene, or indeed loss of the peptide.
- the present invention also encompasses any polypeptide molecule encoded for by the nucleic acid of the present invention and/or produced by the micro-organism of the present invention.
- a recombinant DNA construct comprising the DNA of the present invention cloned into a cloning or expression vector.
- a recombinant micro-organism comprising the recombinant DNA construct of the present invention.
- a Salmonella micro-organism comprising a mutant msbB or htrB. an inactivated msbB or htrB gene or lacking a msbB or htrB gene and having reduced toxicity compared to the parent wild-type, i.e.
- the Salmonella micro-organism is Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi A or C, Salmonella schottmulleri, Salmonella choleraesuis, Salmonella montevideo, Salmonella newport, Salmonella enteritidis, Salmonella gallinarum, Salmonella pullorum, Salmonella abortusovi, Salmonella abortus-equi, Salmonella dublin, Salmonella ofia, Salmonella havana, Salmonella bovis-morbificans, Salmonella hadar, Salmonella arizonae or Salmonella anatum.
- the present invention provides a micro-organism comprising a mutated Salmonella msbB or htrB gene, an inactivated msbB or htrB gene or a micro-organism from which the msbB or htrB gene has been deleted.
- the present invention provides a micro-organism comprising an inactivated msbB or htrB gene: a mutated Salmonella msbB or htrB gene or from which the gene has been deleted, and which results in loss of an msbB encoded protein or htrB encoded protein, respectively; or loss of function of the protein, which in turn results in a lipid A molecule having reduced toxicity.
- the microorganism is Salmonella, Shigella, Klebsiella, Enterobacter. Serratia, Proteus, Yersinia, Vibrio, Aeromonas, Pasteurella. Pseudomonas, Acinetobacter Moraxella,
- Flavobacterium Bordetella, Actinobacillus, Neisseria, Brucella, Haemophilus or Escherichia coli.
- the microorganism is Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi A or C. Salmonella schottmulleri, Salmonella choleraesuis, Salmonella montevideo, Salmonella newport, Salmonella enteritidis, Salmonella gallinarum, Salmonella pullorum, Salmonella abortusovi, Salmonella abortus-equi, Salmonella dublin, Salmonella sofia, Salmonella havana, Salmonella bovis-morbificans, Salmonella hadar. Salmonella arizonae or Salmonella anatum.
- the micro- organism is S. typhimurium, and preferably the strain is C5, SL1344 or HWSH.
- a live vaccine comprising an attenuated or avirulent micro-organism having a mutated msbB or htrB gene, inactivated msbB or htrB gene or lacking the gene and having reduced toxicity in accordance with the present invention.
- the mutation may be introduced into live attenuated vaccine strains of, e.g.
- Salmonella thus reducing their endotoxicity and thereby reducing their reactogenicity. This would generate safer vaccine strains that would be more acceptable to the licensing authorities and to the general public.
- the same strategy might be used for all live attenuated Gram negative bacterial vaccines.
- a prime example here would be the new live attenuated Shigella vaccines. The same effect may arise with an inactivated or deleted gene.
- a method of immunising a subject comprising administering a vaccine of the present invention.
- the vaccine is against infection caused by a micro-organism which is Salmonella, Shigella, Klebsiella, Enterobacter, Serratia, Proteus, Yersinia, Vibrio, Aeromonas, Pasteurella, Pseudomonas.
- the micro-organism is Salmonella typhimurium, Salmonella typhi, Salmonella paratyphi A or C, Salmonella schottmulleri, Salmonella choleraesuis , Salmonella montevideo, Salmonella newport, Salmonella enteritidis.
- the subject may, for example, be a mammal or avian. Examples of such mammals include humans, cattle, swine and ovine species. Examples of such avians include chickens, ducks, turkeys, geese, bantams, quail and pigeons.
- the micro-organism In order to prepare the vaccine of the present invention the micro-organism must be attenuated or rendered avirulent.
- the vaccine composition of the present invention may be administered by injection or orally, and the composition must be suitable for the desired administration route. Suitable vaccine compositions are well known to those skilled in the art.
- Bacteria with mutations in the msbB or htrB gene, an inactivated gene or lacking the gene would provide excellent background strains for the production of proteins and nucleic acid for vaccines and therapeutics, substantially removing the requirement for downstream processing to remove the réellewhile toxic LPS molecules.
- a micro-organism having a mutant msbB or htrB gene, an inactivated gene or lacking said gene and having reduced toxicity in the recombinant production of a protein or gene of interest.
- the isolated LPS made by these mutants may be useful as an endotoxin antagonist.
- Mutants lacking both htrB and msbB may synthesise Lipid IV A - KDO 2 which is a non-toxic antagonist of lipid A. These mutants will thus be a source of this molecule which may be used to treat septic shock resulting from endotoxaemia.
- the present invention also extends to constructs and micro-organisms comprising (i) a mutant msbB gene which results in loss of MsbB protein or the loss of function of the protein; an inactivated msbB gene; or which lacks the msbB gene, in combination with (ii) a mutant htrB gene which results in loss of HtrB protein or loss of the function of the protein; an inactivated htrB gene; or which lacks the htrB gene.
- the present invention also includes the use of such a so-called msbB/htrB double mutant as a vaccine and pharmaceutical compositions comprising it, together with its use in producing genes and proteins of interest.
- the mutations in accordance with the present invention are mutations which are substantially incapable of reversion.
- a substantially non- reversible mutant has a reversion frequency preferably of ⁇ 10 "8 , more preferably ⁇ 10 "9 , even more preferably ⁇ 10 "10 , and most preferably a mutant with zero reversion.
- Figure 1 is a graph showing growth curves of wild-type and msbB mutant S. typhimurium in BALB/c mice. The two growth curves are indistinguishable in the first week of infection. All the mice infected with wild-type organisms died by 1 week post-infection, whereas most of the mice infected with the msbB mutant survived. Subsequently the msbB mutant was cleared from the livers and spleens of infected animals;
- Figures 2a and 2b are graphs representing the in vitro analysis of TNF- ⁇ and IL-ljS. 2xl0 6 cultured J774 macrophage-like cells were incubated with 10 5 msbB mutant or wild-type Salmonella both of which had been heat-killed. A time course of release of TNF- ⁇ and IL-1/3 from these cells in response to the bacteria was determined. Mutant Salmonella induce 5-fold less TNF- ⁇ ( Figure 2a) and half as much IL-1/3 ( Figure 2b) as the wild-type organism;
- Figure 3 is a graph representing NO generation in vitro. 2xl0 6 cultured J774 macrophage-like cells were incubated with 10 7 msbB mutant and wild-type Salmonella that had been heat-killed. Following 24 hours incubation, the culture medium was assayed for NO by the Griess reaction, which detects NO by determining nitrate/nitrite in the medium. Mutant Salmonella induced half as much NO as wild-type bacteria;
- Figures 4a and 4b are graphs representing an in vivo study of cytokines. Serum samples were taken at 24 hours from mice infected with wild-type or msbB mutant organisms. These samples were assayed for TNF- ⁇ ( Figure 4a) and IL-10
- Figure 5 is a graph representing the results of Example 3, an oral vaccination study using an aroA mutant of S. typhimurium in BALB/c mice:
- Figure 6 is another graph representing the results of Example 3, an oral vaccination study using an msbB/aroA mutant of S. typhimurium in BALB/c mice.
- the fatty acyl substitutions in a lipid A molecule of the LPS domain of a bacterium determine the toxicity of the molecule and, furthermore, if alterations in fatty acid substitution could be engineered, then previously toxic LPS molecules may be detoxified.
- Salmonella typhimurium causes a severe invasive disease in mice, which shares many features in common with typhoid fever, caused by S. typhi in humans.
- Mouse typhoid has been extensively investigated, generating a vast amount of data regarding virulence and immunogenicity (4).
- parenteral inoculation into inbred mice several patterns of growth of the bacteria in vivo have been observed, and this growth is controlled by a number of host genetic systems. The best studied of these is that regulated by the Ity gene, which has recently been cloned and named nramp. After intravenous inoculation of S.
- mice typhimurium into mice over 90 % of the inoculum is killed within the first few hours of infection, but the survivors then live and grow within macrophages of the mononuclear phagocyte system (MPS).
- MPS mononuclear phagocyte system
- the rate of growth of the bacteria over the first few days of infection is controlled by nramp such that inbred mice may be divided into susceptible and resistant types.
- Susceptible mice e.g. BALB/c
- Resistant mice e.g.
- LPS and more specifically its lipid A domain, has been described as a potent inducer of all three of these cytokines in many systems. It is possible that the signal inducing the host to begin synthesising these cytokines, and subsequently to control the infection in mouse typhoid, is dependent, at least in part, on the lipid A domain of LPS. This hypothesis has not been established previously for this model.
- a probe based on E. coli msbB DNA sequence was generated using the polymerase chain reaction (PCR), cloned and radiolabelled. This was used to probe a Southern blot of Salmonella typhimurium DNA, identifying a 3.2kb Dral fragment.
- oligonucleotides were also used in a PCR using S. typhimurium DNA as template. This generated an approximately lkb piece of DNA which was cloned into pGEM-T. On sequencing from either end of this construct it was clear from amino acid and DNA sequence homology that this was msbB. To generate an msbB mutant in the S.
- typhimurium chromosome it was first necessary to insert an antibiotic resistance marker into the msbB coding sequence. To do this new oligonucleotides, based on the Salmonella DNA sequence, were generated and used to PCR the gene from the pGEM-T clone. This was then treated with Klenow enzyme to blunt the ends of the DNA and digested with Sail to cut the DNA into 450bp and 550bp fragments. The Sail site is in the coding sequence of the Salmonella msbB gene. A gene cassette encoding kanamycin resistance (Pharmacia) was also cut with Sail.
- the two fragments of the PCR product, the kanamycin resistance cassette and pBluescript that had been digested with EcoRV were then mixed and ligated. This was then transformed into E. coli with selection on ampicillin and kanamycin. Resultant clones were screened for the correct plasmid product. One of these was chosen for further studies. The entire insert from this plasmid was removed using Pvull and cloned into the suicide vector pCVD442 which had been digested with Smal. This was transformed into E. coli carrying the pir gene to allow pCVD442 to replicate. Resultant plasmids were again checked for the correct insert size. One of these was chosen to be used in making the mutant. E.
- coli donor bacteria were conjugated with S. typhimurium LB 5010 recipients using standard methods. After incubating the conjugation mixture, the bacteria were harvested and plated onto selective media containing kanamycin and sucrose.
- pCVD442 contains the sacB gene, the product of which confers sensitivity to the presence of sucrose in the medium. Plating on media containing sucrose thus selects against the presence of vector sequences. Of the colonies that grew on the selection plates, one was picked for further study. To check if the msbB gene has been mutated, chromosomal DNA was prepared and used as template in a PCR using the msbB-specific oligonucleotides.
- the LB 5010 strain is not virulent for mice. It serves as an intermediate in making mutants, since it is mutated in its DNA restriction system, but not its DNA modification system. DNA that passes through LB 5010 is thus modified, which allows a better frequency of introduction of the DNA into its final recipient.
- P22 transduction was used. Briefly, LB 5010 msbBv.Km was infected with P22 HT101 int and plated.
- mice To test the virulence of the S. typhimurium msbB mutant it was injected into nram -susceptible BALB/c mice and its growth in vivo was followed. Mice infected with wild-type organisms died as expected after 7 days of infection with counts in livers and spleens reaching approximately 10 8 per organ ( Figure 1). Intriguingly, the msbB mutants grew at exactly the same rate as the wild-type (w.t.) bacteria, but only caused approximately 5 % of the infected animals to die. Death only occurred when the bacterial counts had reached very high levels (approximately 10 9 per organ).
- J774 macrophage-like cells was measured.
- the cultured cells were incubated with 10 5 heat-killed wild-type or msbB mutant bacteria and the two cytokines were measured in the culture medium by ELISA. It can be seen from Figure 2 that mutant bacteria induced 5-fold less TNF- ⁇ and half as much IL-l ⁇ as their wild-type parents. This is as expected given that the msbB mutant has a reduced toxicity lipid A molecule.
- the release of NO from J774 cells was next determined. Again cultured cells were incubated with 10 7 heat-killed wild-type or msbB mutant bacteria and culture medium was assayed for NO by the Griess' reaction. The mutant bacteria induced half as much NO as the wild-type bacteria ( Figure 3).
- cytokine levels in vivo were measured. At 24 hours post- infection, serum samples were taken and assayed for TNF- ⁇ and IL-l ⁇ using ELISA. These results show that the mutant induced 4-fold less TNF- ⁇ and half as much IL-l ⁇ than the wild-type bacteria. These results correlate precisely with the in vitro results and strongly suggest that the reduced lethality of the msbB mutants is due to their reduced ability to induce potentially harmful cytokine responses: in short, because the toxicity of their lipid A molecule has been reduced. This is the first direct evidence that endotoxin is responsible for lethality in this infection.
- mice/group were inoculated with 10 8 or 10 9 oral by gavage tube S. typhimurium aroA or S. typhimurium aroA/msbB. Animals were left for 30 days and then challenged with wild type 5. typhimurium 10 8 oral by gavage tube. Two separate groups of mice were inoculated as described above but animals in the two groups were killed on days 1, 3, 5, 9, 14, 21 and 28. The livers and spleens of infected mice were homogenised and viable counts performed on the surface of agar plates (see Figures 5 and 6).
- Example 4 Intravenous Challenge of BALB/c mice with S. typhimurium aroA and 5.
- typhimurium msbB i.v. LD50.
- mice were challenged intravenously with 5.
- Mice were left and observed for deaths in all groups.
- S. typhimurium aroA and aroA/msbB all lived at doses up to 10 6 i.v. All of both sets of mutants died at 10 7 i.v. but the msbB group lived significantly longer than the aroA infected group.
- S. typhimurium aroA infected mice died at day 7 but the msbB group lived up to 3 weeks after the aroA group died.
- Raetz CRH The enzymatic synthesis of lipid A. In Levin J, Alving CR, Munford RS and Stutz PL (eds) Bacterial Endotoxin: Recognition and Effector
- Hormaeche CE Villareal B Mastroeni, P, Dougan G. Chatfield SN. Immunity mechanisms in experimental salmonellosis. In Cabello F, Hormaeche CE, Mastroeni P, Bonina L (eds) Biology of Salmonella. New York: Plenum Press, 1993: pp 223-335. 5. Hormaeche CE, Mastroeni P, Arena A, Uddin J, Joysey HS. T-cells do not mediate the initial suppression of a Salmonella infection in the RES. Immunology 1990; 70: 247-250.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9701886 | 1997-01-30 | ||
GBGB9701886.5A GB9701886D0 (en) | 1997-01-30 | 1997-01-30 | Nucleic acid |
GBGB9701887.3A GB9701887D0 (en) | 1997-01-30 | 1997-01-30 | Nucleic acid |
GB9701887 | 1997-01-30 | ||
PCT/GB1998/000291 WO1998033923A1 (en) | 1997-01-30 | 1998-01-30 | MUTANT msbB or htrB GENES |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0973911A1 true EP0973911A1 (en) | 2000-01-26 |
Family
ID=26310892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98902105A Withdrawn EP0973911A1 (en) | 1997-01-30 | 1998-01-30 | MUTANT $i(msbB) or $i(htrB) GENES |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0973911A1 (en) |
AU (1) | AU5873498A (en) |
WO (1) | WO1998033923A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9200289B1 (en) | 2009-02-09 | 2015-12-01 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system and method improving the therapeutic activity and specificity of proteins and phage and phagemids delivered by bacteria |
US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
US9878023B1 (en) | 2010-02-09 | 2018-01-30 | David Gordon Bermudes | Protease inhibitor: protease sensitive expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
US10087451B2 (en) | 2006-09-22 | 2018-10-02 | Aviex Technologies Llc | Live bacterial vectors for prophylaxis or treatment |
US10188722B2 (en) | 2008-09-18 | 2019-01-29 | Aviex Technologies Llc | Live bacterial vaccines resistant to carbon dioxide (CO2), acidic pH and/or osmolarity for viral infection prophylaxis or treatment |
US10364435B1 (en) | 2010-02-09 | 2019-07-30 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999013053A1 (en) | 1997-09-10 | 1999-03-18 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
GB9918319D0 (en) * | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
US6962696B1 (en) | 1999-10-04 | 2005-11-08 | Vion Pharmaceuticals Inc. | Compositions and methods for tumor-targeted delivery of effector molecules |
KR20070091698A (en) | 2000-06-29 | 2007-09-11 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | Multivalent vaccine composition |
TWI457133B (en) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | Novel composition |
US9597379B1 (en) | 2010-02-09 | 2017-03-21 | David Gordon Bermudes | Protease inhibitor combination with therapeutic proteins including antibodies |
KR101856736B1 (en) * | 2016-02-29 | 2018-05-11 | (주)비손바이오로직스 | Endotoxin-reduced Salmonella trivalent inactivated vaccine composition for preventing fowl typhoid and Salmonellosis |
KR102264989B1 (en) * | 2019-05-31 | 2021-06-15 | 강원대학교 산학협력단 | Endotoxin-reduced Escherichia coli trivalent inactivated vaccine composition for preventing Avian colibacillosis |
KR20220159914A (en) * | 2021-05-26 | 2022-12-05 | 서울대학교산학협력단 | Attenuated Salmonella Gallinarum mutant strains and uses thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6887483B2 (en) * | 1995-12-01 | 2005-05-03 | University Of Iowa Research Foundation | Non-toxic mutants of pathogenic gram-negative bacteria |
-
1998
- 1998-01-30 WO PCT/GB1998/000291 patent/WO1998033923A1/en not_active Application Discontinuation
- 1998-01-30 EP EP98902105A patent/EP0973911A1/en not_active Withdrawn
- 1998-01-30 AU AU58734/98A patent/AU5873498A/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO9833923A1 * |
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10087451B2 (en) | 2006-09-22 | 2018-10-02 | Aviex Technologies Llc | Live bacterial vectors for prophylaxis or treatment |
US10188722B2 (en) | 2008-09-18 | 2019-01-29 | Aviex Technologies Llc | Live bacterial vaccines resistant to carbon dioxide (CO2), acidic pH and/or osmolarity for viral infection prophylaxis or treatment |
US11485773B1 (en) | 2009-02-09 | 2022-11-01 | David Gordon Bermudes | Protease inhibitor:protease sensitive expression system and method improving the therapeutic activity and specificity of proteins and phage and phagemids delivered by bacteria |
US9200289B1 (en) | 2009-02-09 | 2015-12-01 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system and method improving the therapeutic activity and specificity of proteins and phage and phagemids delivered by bacteria |
US9657085B1 (en) | 2009-02-09 | 2017-05-23 | David Gordon Bermudes | Protease inhibitor: protease sensitive expression system and method improving the therapeutic activity and specificity of proteins and phage and phagemids delivered by bacteria |
US10590185B1 (en) | 2009-02-09 | 2020-03-17 | David Gordon Bermudes | Protease inhibitor: protease sensitive expression system and method improving the therapeutic activity and specificity of proteins and phage and phagemids delivered by bacteria |
US11219671B1 (en) | 2010-02-09 | 2022-01-11 | David Gordon Bermudes | Protease inhibitor:protease sensitive expression system, composition and methods for improving the therapeutic activity and specificity of proteins delivered by bacteria |
US10954521B1 (en) | 2010-02-09 | 2021-03-23 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US10364435B1 (en) | 2010-02-09 | 2019-07-30 | David Gordon Bermudes | Immunization and/or treatment of parasites and infectious agents by live bacteria |
US9878023B1 (en) | 2010-02-09 | 2018-01-30 | David Gordon Bermudes | Protease inhibitor: protease sensitive expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
US11827890B1 (en) | 2013-02-14 | 2023-11-28 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
US10501746B1 (en) | 2013-02-14 | 2019-12-10 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
US9593339B1 (en) | 2013-02-14 | 2017-03-14 | David Gordon Bermudes | Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment |
US9737592B1 (en) | 2014-02-14 | 2017-08-22 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
US10828350B1 (en) | 2014-02-14 | 2020-11-10 | David Gordon Bermudes | Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment |
US10828356B1 (en) | 2014-09-18 | 2020-11-10 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US10729731B1 (en) | 2014-09-18 | 2020-08-04 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US11633435B1 (en) | 2014-09-18 | 2023-04-25 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US11813295B1 (en) | 2014-09-18 | 2023-11-14 | Theobald Therapeutics LLC | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US10449237B1 (en) | 2014-09-18 | 2019-10-22 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
US11471497B1 (en) | 2019-03-13 | 2022-10-18 | David Gordon Bermudes | Copper chelation therapeutics |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
US11406702B1 (en) | 2020-05-14 | 2022-08-09 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated Salmonella as a vaccine |
Also Published As
Publication number | Publication date |
---|---|
WO1998033923A1 (en) | 1998-08-06 |
AU5873498A (en) | 1998-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0973911A1 (en) | MUTANT $i(msbB) or $i(htrB) GENES | |
AU623599B2 (en) | Avirulent microbes, incapable of producing functional adenylate cyclase and cyclic amp | |
CA1339412C (en) | Method for screening an expression cdna clone bank for the detection of polynucleotides | |
KR100202771B1 (en) | Live vaccine | |
US5294441A (en) | Avirulent microbes and uses therefor: salmonella typhi | |
US6399074B1 (en) | Live attenuated salmonella vaccines to control avian pathogens | |
ES2248825T3 (en) | NON-TOXIC MUTANTS OF GRAM NEGATIVE PATHOGEN BACTERIA. | |
US6537558B2 (en) | Methods of producing and using virulence attenuated poxR mutant bacteria | |
US5855880A (en) | Avirulent microbes and uses therefor | |
US9764021B2 (en) | Methods of using Salmonella enterica presenting C. jejuni N-glycan or derivatives thereof | |
EP0500699B1 (en) | Cross-protective salmonella vaccines | |
EP0563311B1 (en) | Improved vaccines | |
WO1997019688A9 (en) | Non-toxic mutants of pathogenic gram-negative bacteria | |
AU666108B2 (en) | CDT mutants of salmonella typhi | |
US7597896B2 (en) | Composition comprising a protein encoded by a modified ERP gene of Mycobacterium | |
EP1037664B1 (en) | Vaccines containing attenuated bacteria | |
US6905691B1 (en) | Vaccines containing attenuated bacteria | |
Jankovic | Characterisation of the lex2B gene and its role in LPS biosynthesis in Campylobacter jejuni. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19990826 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT SE |
|
RTI1 | Title (correction) |
Free format text: MUTANT MSBB OR HTRB GENES |
|
17Q | First examination report despatched |
Effective date: 20030730 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RTI1 | Title (correction) |
Free format text: LIVE VACCINNE COMPRISING MUTANT MSBB AND/OR HTRB GENES |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61K 39/02 A |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: DOUGAN, GORDON,IMPERIAL COL. OF SCI., TECH.& M Inventor name: MASKELL, DUNCAN, JOHN |
|
RTI1 | Title (correction) |
Free format text: LIVE VACCINE COMPRISING MUTANT MSBB AND/OR HTRB GENES |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050421 |